Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis
NCT ID: NCT06134544
Last Updated: 2024-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
18 participants
INTERVENTIONAL
2023-11-25
2024-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fecal Microbiota Transplantation for Decompensated Cirrhosis
NCT03014505
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
NCT02721264
Probiotics in the Treatment of NAFLD
NCT02764047
Fecal Microbiome Transplantation in Cirrhosis: Trial in Patients With Decompensated Cirrhosis
NCT06533852
Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.
NCT02868164
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Administration of IMO
Patients will be given IMO (20g/100ml) for 7 days.
Isomaltooligosaccharides (IMO)
Patients will still receive standard treatment, including medicine and other invasive treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Isomaltooligosaccharides (IMO)
Patients will still receive standard treatment, including medicine and other invasive treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cirrhotic patients.
* Decompensation event: ascites.
* LPS\>0.45EU/ml.
Exclusion Criteria
* Active bacterial or fungal infection.
* Other decompensations: Hepatic encephalopathy, gastroesophageal varices and hemorrhage.
* Diagnosis of EASL-ACLF.
* Diarrhea.
* Malignancy.
* Anticipated short survival time.
* Adverse reactions or allergies to oral carbohydrate preparations.
* Substance abuse or addiction.
* Severe extrahepatic diseases (e.g. patients with CKD-5 stage, severe cardiopulmonary dysfunction, and psychiatric disorders).
* Be immunosuppressed or immunodeficient states and the use of immunoglobulins or other immune-boosting conditions.
* Be unsuitable for participating in this trial.
* Participated in any drug trial within the past month
* History of antibacterial or fungal use within 1 week prior to screening
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanfang Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NFEC-2023-457
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.